Lewis A. Conner Memorial Lecture. Oxidative modification of LDL and atherogenesis.

I want to express my thanks to Dr Sidney Smith, President of the American Heart Association, for selecting me to present the 1995 Conner Memorial Lecture. I want also to express my admiration for and gratitude to this remarkable organization, the American Heart Association, and its wonderful staff, with whom I have worked for more than 30 years. I have missed very few AHA meetings since 1959 when the American Society for Study of Arteriosclerosis became the American Heart Association Council on Arteriosclerosis. I−indeed all of us−owe a great debt to the AHA for its tireless efforts over the years to support medical research and improve medical care. I start with the assumption that we can all agree that hypercholesterolemia−particularly hyperbetalipoproteinemia−is an important causative factor in atherogenesis and that correction of it can strikingly reduce the risk of coronary heart disease (CHD). Yet it was not so long ago that this argument had to be vigorously defended. It was only in 1983 that the National Institutes of Health (NIH) officially endorsed the position that hypercholesterolemia must be treated. That decision followed closely on the completion of the landmark Lipid Research Clinic Intervention Trial, initiated by Dr Donald S. Fredrickson and Dr Robert I. Levy and shepherded to completion by Dr Basil Rifkind.1 The following year I had the privilege of chairing the NIH Consensus Conference on Lowering Blood Cholesterol,2 which concluded unanimously that there was an unarguable cause-and-effect relationship and that lowering blood cholesterol should be an important national goal. The following year the National Heart, Lung, and Blood Institute (NHLBI) organized and spearheaded the National Cholesterol Education Program (NCEP). Actually this year marks the 10th anniversary of the NCEP, and I think we can again all agree that it has accomplished a great deal under the able …

[1]  D. Steinberg,et al.  Cell surface expression of mouse macrosialin and human CD68 and their role as macrophage receptors for oxidized low density lipoprotein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[2]  D. Steinberg Oxidized low density lipoprotein--an extreme example of lipoprotein heterogeneity. , 1996, Israel journal of medical sciences.

[3]  G. Omenn,et al.  Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. , 1996, The New England journal of medicine.

[4]  J. Manson,et al.  Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. , 1996, The New England journal of medicine.

[5]  F. Kelly,et al.  Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS) , 1996, The Lancet.

[6]  S. Bhakdi,et al.  On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety , 1995, The Journal of experimental medicine.

[7]  C. Furberg,et al.  Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. , 1995, Circulation.

[8]  D. Steinberg,et al.  The 94- to 97-kDa mouse macrophage membrane protein that recognizes oxidized low density lipoprotein and phosphatidylserine-rich liposomes is identical to macrosialin, the mouse homologue of human CD68. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[9]  S. Yamashita,et al.  Reduced uptake of oxidized low density lipoproteins in monocyte-derived macrophages from CD36-deficient subjects. , 1995, The Journal of clinical investigation.

[10]  D. Steinberg,et al.  Effect of the antioxidant N,N'-diphenyl 1,4-phenylenediamine (DPPD) on atherosclerosis in apoE-deficient mice. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[11]  T. Carew,et al.  Effect of vitamin E on atherogenesis in LDL receptor-deficient rabbits. , 1995, Atherosclerosis.

[12]  P. Libby,et al.  Evidence for apoptosis in advanced human atheroma. Colocalization with interleukin-1 beta-converting enzyme. , 1995, The American journal of pathology.

[13]  P. Edwards,et al.  Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. , 1995, Circulation.

[14]  G. Evan,et al.  Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. , 1995, The Journal of clinical investigation.

[15]  R. Parker,et al.  Relation of vascular oxidative stress, alpha-tocopherol, and hypercholesterolemia to early atherosclerosis in hamsters. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[16]  D. Steinberg,et al.  Recognition of oxidatively damaged and apoptotic cells by an oxidized low density lipoprotein receptor on mouse peritoneal macrophages: role of membrane phosphatidylserine. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[17]  P. Demacker,et al.  Vitamin E and fatty acid intervention does not attenuate the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[18]  R. Silverstein,et al.  Oxidized LDL binds to CD36 on human monocyte-derived macrophages and transfected cell lines. Evidence implicating the lipid moiety of the lipoprotein as the binding site. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[19]  P. Libby,et al.  Cytokines Regulate Genes Involved in Atherogenesis a , 1994, Annals of the New York Academy of Sciences.

[20]  P. Libby,et al.  Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. , 1994, The Journal of clinical investigation.

[21]  S. Nilsson,et al.  The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). , 1994, The American journal of cardiology.

[22]  D. Morel,et al.  Treatment of cholesterol-fed rabbits with dietary vitamins E and C inhibits lipoprotein oxidation but not development of atherosclerosis. , 1994, The Journal of nutrition.

[23]  M. Penn,et al.  Oxidized lipoproteins, altered cell function and atherosclerosis. , 1994, Atherosclerosis.

[24]  P. Wahl,et al.  Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. I. Is the extent of atherosclerosis related to resistance of LDL to oxidation? , 1994, The Journal of clinical investigation.

[25]  T. Carew,et al.  A comparison of the antiatherogenic effects of probucol and of a structural analogue of probucol in low density lipoprotein receptor-deficient rabbits. , 1994, The Journal of clinical investigation.

[26]  J. Stengård,et al.  Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.

[27]  D. Steinberg,et al.  Recognition of oxidatively damaged erythrocytes by a macrophage receptor with specificity for oxidized low density lipoprotein. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[28]  K. Prasad,et al.  Oxygen free radicals as a mechanism of hypercholesterolemic atherosclerosis: Effects of probucol , 1994 .

[29]  T. Buttke,et al.  Oxidative stress as a mediator of apoptosis. , 1994, Immunology today.

[30]  D. Albanes,et al.  The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. , 1994, The New England journal of medicine.

[31]  D. Steinberg,et al.  Oxidatively modified low density lipoprotein is a chemoattractant for human T lymphocytes. , 1993, The Journal of clinical investigation.

[32]  J. Mckenney,et al.  Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) , 1993, JAMA.

[33]  L. Stanton,et al.  CD36 is a receptor for oxidized low density lipoprotein. , 1993, The Journal of biological chemistry.

[34]  J. Fawcett,et al.  Macrosialin, a mouse macrophage-restricted glycoprotein, is a member of the lamp/lgp family. , 1993, The Journal of biological chemistry.

[35]  R. Ross The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[36]  K. Prasad,et al.  Oxygen free radicals and hypercholesterolemic atherosclerosis: effect of vitamin E. , 1993, American heart journal.

[37]  P. Reaven,et al.  Effect of dietary antioxidant combinations in humans. Protection of LDL by vitamin E but not by beta-carotene. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[38]  P. Libby,et al.  An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[39]  C. Haslett,et al.  Phagocyte recognition of cells undergoing apoptosis. , 1993, Immunology today.

[40]  C. Haslett,et al.  Different populations of macrophages use either the vitronectin receptor or the phosphatidylserine receptor to recognize and remove apoptotic cells. , 1992, Journal of immunology.

[41]  L. Stanton,et al.  A macrophage Fc receptor for IgG is also a receptor for oxidized low density lipoprotein. , 1992, The Journal of biological chemistry.

[42]  J L Witztum,et al.  Monoclonal antibodies against LDL further enhance macrophage uptake of LDL aggregates. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[43]  Margaret S. Wu,et al.  Low density lipoprotein is protected from oxidation and the progression of atherosclerosis is slowed in cholesterol-fed rabbits by the antioxidant N,N'-diphenyl-phenylenediamine. , 1992, The Journal of clinical investigation.

[44]  Verlangieri Aj,et al.  Effects of d-alpha-tocopherol supplementation on experimentally induced primate atherosclerosis. , 1992 .

[45]  H. Horstmann,et al.  Immunocytochemical characterization of the endocytic and phagolysosomal compartments in peritoneal macrophages , 1992, The Journal of cell biology.

[46]  S. Rankin,et al.  Role of oxidized low density lipoprotein in atherogenesis. , 1992, Progress in lipid research.

[47]  M. Davies,et al.  Anatomic features in victims of sudden coronary death. Coronary artery pathology. , 1992, Circulation.

[48]  A. Chait,et al.  Phagocytosis of lipase-aggregated low density lipoprotein promotes macrophage foam cell formation. Sequential morphological and biochemical events. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[49]  S. Gordon,et al.  Macrosialin, a macrophage-restricted membrane sialoprotein differentially glycosylated in response to inflammatory stimuli [published erratum appears in J Exp Med 1992 Jan 1;175(1):309] , 1991, The Journal of experimental medicine.

[50]  S. Mao,et al.  Attenuation of atherosclerosis in a modified strain of hypercholesterolemic Watanabe rabbits with use of a probucol analogue (MDL 29,311) that does not lower serum cholesterol. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[51]  H. Esterbauer,et al.  Effect of oral supplementation with D-alpha-tocopherol on the vitamin E content of human low density lipoproteins and resistance to oxidation. , 1991, Journal of lipid research.

[52]  M. Freeman,et al.  Expression of type I and type II bovine scavenger receptors in Chinese hamster ovary cells: lipid droplet accumulation and nonreciprocal cross competition by acetylated and oxidized low density lipoprotein. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[53]  A Daugherty,et al.  The effects of probucol on the progression of atherosclerosis in mature Watanabe heritable hyperlipidaemic rabbits , 1991, British journal of pharmacology.

[54]  A. Tall,et al.  Increase in plasma cholesteryl ester transfer protein during probucol treatment. Relation to changes in high density lipoprotein composition. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[55]  M. Cybulsky,et al.  Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. , 1991, Science.

[56]  P. Henriksson,et al.  The antioxidant butylated hydroxytoluene protects against atherosclerosis. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[57]  S. Mao,et al.  Antioxidant activity of probucol and its analogues in hypercholesterolemic Watanabe rabbits. , 1991, Journal of medicinal chemistry.

[58]  S. Mao,et al.  Probucol and its mechanisms for reducing atherosclerosis. , 1991, Advances in experimental medicine and biology.

[59]  J L Witztum,et al.  Lipoproteins and atherogenesis. Current concepts. , 1990, JAMA.

[60]  S. Cribier,et al.  Control of the transmembrane phospholipid distribution in eukaryotic cells by aminophospholipid translocase , 1990, Biotechnology and applied biochemistry.

[61]  A. J. Valente,et al.  Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[62]  S. Ylä-Herttuala,et al.  Distribution of oxidation specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. , 1990, Arteriosclerosis.

[63]  D. Steinberg,et al.  Prevention of low density lipoprotein aggregation by high density lipoprotein or apolipoprotein A-I. , 1990, Journal of lipid research.

[64]  A. Lusis,et al.  Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins , 1990, Nature.

[65]  M. Freeman,et al.  Type I macrophage scavenger receptor contains α-helical and collagen-like coiled coils , 1990, Nature.

[66]  D. Steinberg,et al.  Lipoproteins in normal and atherosclerotic aorta. , 1990, European heart journal.

[67]  D. Steinberg,et al.  The cholesterol controversy is over. Why did it take so long? , 1989, Circulation.

[68]  A Daugherty,et al.  Probucol attenuates the development of aortic atherosclerosis in cholesterol‐fed rabbits , 1989, British journal of pharmacology.

[69]  J L Witztum,et al.  Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. , 1989, The Journal of clinical investigation.

[70]  J L Witztum,et al.  Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. , 1989, The New England journal of medicine.

[71]  A. Chait,et al.  Phagocytosis of aggregated lipoprotein by macrophages: low density lipoprotein receptor-dependent foam-cell formation. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[72]  S. Narumiya,et al.  Multiple receptors for modified low density lipoproteins in mouse peritoneal macrophages: different uptake mechanisms for acetylated and oxidized low density lipoproteins. , 1989, Biochemical and biophysical research communications.

[73]  D. Steinberg,et al.  A macrophage receptor that recognizes oxidized low density lipoprotein but not acetylated low density lipoprotein. , 1989, The Journal of biological chemistry.

[74]  J L Witztum,et al.  Low density lipoprotein undergoes oxidative modification in vivo. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[75]  O. Stein,et al.  Lack of effect of probucol on atheroma formation in cholesterol-fed rabbits kept at comparable plasma cholesterol levels. , 1989, Atherosclerosis.

[76]  M. Lopes-Virella,et al.  Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes. A possible mechanism of foam cell formation , 1988, The Journal of experimental medicine.

[77]  M. Haberland,et al.  Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. , 1988, Science.

[78]  D. Steinberg,et al.  Enhanced Macrophage Uptake of Low Density Lipoprotein after Self‐Aggregation , 1988, Arteriosclerosis.

[79]  T. Carew,et al.  Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[80]  G. Camejo,et al.  Effect of arterial proteoglycans on the interaction of LDL with human monocyte-derived macrophages. , 1987, Atherosclerosis.

[81]  A. Ooshima,et al.  Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[82]  D. Steinberg,et al.  Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[83]  G. Koch,et al.  Differential expression of murine macrophage surface glycoprotein antigens in intracellular membranes. , 1987, Journal of cell science.

[84]  P. Williamson,et al.  Membrane phospholipid asymmetry as a determinant of erythrocyte recognition by macrophages. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[85]  A. G. Vinogradov,et al.  Lipoprotein-antibody immune complexes. Their catabolism and role in foam cell formation. , 1985, Atherosclerosis.

[86]  J. Hupp Lowering Blood Cholesterol to Prevent Heart Disease , 1985, International Journal of Technology Assessment in Health Care.

[87]  B. Rifkind Lipid Research Clinics Coronary Primary Prevention Trial: results and implications. , 1984, The American journal of cardiology.

[88]  D. Morel,et al.  Endothelial and Smooth Muscle Cells Alter Low Density Lipoprotein In Vitro by Free Radical Oxidation , 1984, Arteriosclerosis.

[89]  J L Witztum,et al.  Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[90]  I. Fidler,et al.  The recognition of red blood cells by macrophages: role of phosphatidylserine and possible implications of membrane phospholipid asymmetry , 1984, Biology of the cell.

[91]  L. J. Lewis,et al.  Lipoprotein Oxidation and Lipoprotein‐lnduced Cytotoxicity , 1983, Arteriosclerosis.

[92]  D. Steinberg,et al.  Enhanced Macrophage Degradation of Biologically Modified Low Density Lipoprotein , 1983, Arteriosclerosis.

[93]  M. Brown,et al.  Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. , 1983, Annual review of biochemistry.

[94]  D. Steinberg,et al.  INTERACTIONS OF PLASMA LIPOPROTEINS WITH ENDOTHELIAL CELLS * , 1982, Annals of the New York Academy of Sciences.

[95]  D. Steinberg,et al.  Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[96]  M. Brown,et al.  Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[97]  T. Carew,et al.  Uptake and degradation of low density lipoprotein by swine arterial smoot muscle cells with inhibition of cholesterol biosynthesis. , 1976, Biochimica et biophysica acta.